The ClinicianThe ClinicianКлиницист1818-83382412-8775Publishing House ABV Press19310.17650/1818-8338-2015-9-2-36-39LECTIONЛЕКЦИЯBACK PAIN SYNDROME: MODERN APPROACHES TO THERAPYБОЛЕВОЙ СИНДРОМ В СПИНЕ: СОВРЕМЕННЫЕ ПОДХОДЫ К ТЕРАПИИShostakN. A.ШостакН. А.
Russian Federation
shostakkaf@yandex.ruKlimenkoA. A.КлименкоА. А.
Russian Federation
Acad. A.I. Nesterov Department of Faculty Therapy, N.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaКафедра факультетской терапии им. акад. А.И. Нестерова ГБОУ ВПО «РНИМУ им. Н.И. Пирогова» Минздрава России1 Ostrovityanov St., Moscow, 117997, RussiaРоссия, 117997, Москва, ул. Островитянова, 1150420159236391308201513082015Copyright ©; 2015, Shostak N.A., Klimenko A.A.Copyright ©; 2015, Шостак Н.А., Клименко А.А.2015Shostak N.A., Klimenko A.A.Шостак Н.А., Клименко А.А.https://creativecommons.org/licenses/by/4.0https://klinitsist.abvpress.ru/Klin/article/view/193

Objective: to describe management tactics in patients with back pain syndrome and to give recommendations for the choice of non-drug and drug treatments (with main drug groups) and the duration of a treatment cycle. Materials and methods. The paper considers the basic mechanisms and causes of back pain syndromes (dorsalgias). It introduces the concept “dorsopathy” that characterizes the appearance of nonvisceral pain syndrome in the extremities and trunk, which is caused by degenerative processes in the vertebral motion segment. The authors provide a description of spondyloarthrosis, one of the main degenerative diseases of the spine, and give current principles of treatment for the major symptoms of the disease. Results. The main goal of treatment in patients with back pain is to relieve pain syndrome. Selective nonsteroidal anti-inflammatory drugs are the medicaments of choice. Conclusion. This paper covers current approaches to managing patients with spondyloarthrosis and gives recommendations regarding the treatment of the major disease manifestation – pain syndrome. 

back paindorsopathydorsalgiaspondyloarthrosisradiculopathymyofascial painnonsteroidal anti-inflammatory drugsmeloxicammovalisболь в спинедорсопатиядорсалгияспондилоартрозрадикулопатиямиофасциальная больнестероидные противовоспалительные препаратымелоксикаммовалис1. Шостак Н.А., Правдюк Н.Г. Дорсопатии: новый взгляд на проблему диагностики и лечения. Современная ревматология 2010;1:28–31. [Shostak N.A., Pravdyuk N.G. Dorsopathies: a new view of the problem of diagnostics and treatment. Sovremennaya revmatologiya = Modern Rheumatology 2010;1:28–31. (In Russ.)].Шостак Н.А., Правдюк Н.Г. Дорсопатии: новый взгляд на проблему диагностики и лечения. Современная ревматология 2010;1:28–31. [Shostak N.A., Pravdyuk N.G. Dorsopathies: a new view of the problem of diagnostics and treatment. Sovremennaya revmatologiya = Modern Rheumatology 2010;1:28–31. (In Russ.)].2. Шостак Н.А., Правдюк Н.Г. Роль мышечного спазма в формировании болевого синдрома при спондилоартрозе. Русский медицинский журнал 2005;10:15–8. [Shostak N.A., Pravdyuk N.G. The role of muscular spasm in formation of the pain syndrome with spondylarthrosis. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2005;10:15–8. (In Russ.)].Шостак Н.А., Правдюк Н.Г. Роль мышечного спазма в формировании болевого синдрома при спондилоартрозе. Русский медицинский журнал 2005;10:15–8. [Shostak N.A., Pravdyuk N.G. The role of muscular spasm in formation of the pain syndrome with spondylarthrosis. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2005;10:15–8. (In Russ.)].3. Yang H., Liu H., Li Z. et al. Low back pain associated with lumbar disc herniation: role of moderately degenerative disc and annulus fibrous tears. Int J Clin Exp Med 2015;8(2):1634–44.Yang H., Liu H., Li Z. et al. Low back pain associated with lumbar disc herniation: role of moderately degenerative disc and annulus fibrous tears. Int J Clin Exp Med 2015;8(2):1634–44.4. Rodeghero J.R., Cook C.E., Cleland J.A., Mintken P.E. Risk stratification of patients with low back pain seen in physical therapy practice. Man Ther 2015.Rodeghero J.R., Cook C.E., Cleland J.A., Mintken P.E. Risk stratification of patients with low back pain seen in physical therapy practice. Man Ther 2015.5. Бадокин В.В. Применение Сирдалуда в ревматологической практике. Русский медицинский журнал 2005;24:1586–9. [Badokin V.V. Application of Sirdalud in rheumatological practice. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2005;24:1586–9. (In Russ.)].Бадокин В.В. Применение Сирдалуда в ревматологической практике. Русский медицинский журнал 2005;24:1586–9. [Badokin V.V. Application of Sirdalud in rheumatological practice. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2005;24:1586–9. (In Russ.)].6. Камчатнов П.Р., Умарова Х.Я. Поясничная боль – повышение эффективности терапии. Клиницист 2013;1:64–8. [Kamchatnov P.R., Umarova Kh.Ya. Lumbar pain: increasing of therapy efficiency. Klinitsist = Clinicist 2013;1:64–8. (In Russ.)].Камчатнов П.Р., Умарова Х.Я. Поясничная боль – повышение эффективности терапии. Клиницист 2013;1:64–8. [Kamchatnov P.R., Umarova Kh.Ya. Lumbar pain: increasing of therapy efficiency. Klinitsist = Clinicist 2013;1:64–8. (In Russ.)].7. Zeidler H., Kaltwasser J.P., Leonard J.P. et al. Prescription and tolerability of meloxicam in day-to-day practice: postmarketing observational cohort study of 13,307 patients in Germany. J Clin Rheumatol 2002;8(6):305–15.Zeidler H., Kaltwasser J.P., Leonard J.P. et al. Prescription and tolerability of meloxicam in day-to-day practice: postmarketing observational cohort study of 13,307 patients in Germany. J Clin Rheumatol 2002;8(6):305–15.8. Singh G., Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl 1999;56:18–24.Singh G., Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl 1999;56:18–24.9. Насонов Е.Л., Лазебник Л.Б., Беленков Ю.Н. и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М.: Алмаз, 2006. [Nasonov E.L., Lazebnik L.B., Belenkov Yu.N. et al. Application of nonsteroidal anti-inflammatory drugs. Clinical Recommendations. Moscow: Almaz, 2006. (In Russ.)].Насонов Е.Л., Лазебник Л.Б., Беленков Ю.Н. и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М.: Алмаз, 2006. [Nasonov E.L., Lazebnik L.B., Belenkov Yu.N. et al. Application of nonsteroidal anti-inflammatory drugs. Clinical Recommendations. Moscow: Almaz, 2006. (In Russ.)].10. Janssen M., Dijkmans B.A., van der Sluys F.A. et al. Upper gastrointestinal complaints and complication in chronic rheumatic patients in comparison with other chronic diseases. Br J Rheumatol 1992;31(11):747–52.Janssen M., Dijkmans B.A., van der Sluys F.A. et al. Upper gastrointestinal complaints and complication in chronic rheumatic patients in comparison with other chronic diseases. Br J Rheumatol 1992;31(11):747–52.11. Schoenfeld P. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am J Med 1999;107(6A):48–54S.Schoenfeld P. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am J Med 1999;107(6A):48–54S.12. Layton D., Heely E., Hughes K., Shakir S.A. Comparison of the incidence of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (Oxf) 2003;42(11): 1342–53.Layton D., Heely E., Hughes K., Shakir S.A. Comparison of the incidence of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (Oxf) 2003;42(11): 1342–53.13. Singh G. Meloxicam does not increase the risk of acute myocardial infarction, congestive heart failure, edema or hypertension compared to NSAIDs: results from a pooled analysis of 27039 patients. Eur Congress of Rheumatology, Prague, 13–16 June, 2001.Singh G. Meloxicam does not increase the risk of acute myocardial infarction, congestive heart failure, edema or hypertension compared to NSAIDs: results from a pooled analysis of 27039 patients. Eur Congress of Rheumatology, Prague, 13–16 June, 2001.14. Van Ryn J., Kink-Einbad M., Kuritsch I. et al. Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. J Clin Pharmacol 2004;44(7):777–84.Van Ryn J., Kink-Einbad M., Kuritsch I. et al. Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. J Clin Pharmacol 2004;44(7):777–84.15. Altman R., Luciardi H.L., Muntaner J. et al. Efficacy assessment of meloxicam, a preferential cyclooxigenese-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the non-steroidal anti-inflammatory drugs in instable angina treatment-2 (NUT-2) pilot study. Circulation 2002;106(2):191–5.Altman R., Luciardi H.L., Muntaner J. et al. Efficacy assessment of meloxicam, a preferential cyclooxigenese-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the non-steroidal anti-inflammatory drugs in instable angina treatment-2 (NUT-2) pilot study. Circulation 2002;106(2):191–5.16. Combe B., Velicitat P., Garson N., Bluhmki E. Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients. Inflamm Res 2001;50 Suppl 1:S10–6.Combe B., Velicitat P., Garson N., Bluhmki E. Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients. Inflamm Res 2001;50 Suppl 1:S10–6.17. Цветкова Е.С. Эффективность и переносимость ступенчатой терапии мовалисом (мелоксикамом) при ревматических заболеваниях. Терапевтический архив 2004;76(12):78–80. [Tsvetkova E.S. Efficiency and tolerance of the sequential therapy with movalis (meloxicam) with rheumatic diseases. Terapevticheskiy arkhiv = Therapeutic Archive 2004;76(12):78–80. (In Russ.)].Цветкова Е.С. Эффективность и переносимость ступенчатой терапии мовалисом (мелоксикамом) при ревматических заболеваниях. Терапевтический архив 2004;76(12):78–80. [Tsvetkova E.S. Efficiency and tolerance of the sequential therapy with movalis (meloxicam) with rheumatic diseases. Terapevticheskiy arkhiv = Therapeutic Archive 2004;76(12):78–80. (In Russ.)].18. Алексеев В.В. Применение мелоксикама в лечении люмбоишалгического синдрома. Русский медицинский журнал 2003;11(7):416–8. [Alexeyev V.V. Application of meloxicam for treatment of lumb ischemia. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2003;11(7):416–8. (In Russ.)].Алексеев В.В. Применение мелоксикама в лечении люмбоишалгического синдрома. Русский медицинский журнал 2003;11(7):416–8. [Alexeyev V.V. Application of meloxicam for treatment of lumb ischemia. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2003;11(7):416–8. (In Russ.)].19. Singh G., Lanes S., Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. Am J Med 2004;117(2):100–6.Singh G., Lanes S., Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. Am J Med 2004;117(2):100–6.20. Rinder H.M., Tracey J.B., Souhrada M. et al. Effects of meloxicam on platelet function in healthy adults: a randomized, double-blind, placebocontrolled trial. J Clin Pharmacol 2002;42(8):881–6.Rinder H.M., Tracey J.B., Souhrada M. et al. Effects of meloxicam on platelet function in healthy adults: a randomized, double-blind, placebocontrolled trial. J Clin Pharmacol 2002;42(8):881–6.21. Шостак Н.А., Клименко А.А. Нестероидные противовоспалительные препараты – современные аспекты их применения. Клиницист 2013;3–4:53–61. [Shostak N.A., Klimenko A.A. Non-steroidal antiinflammatory drugs: modern aspects of their application. Klinitsist = Clinicist 2013; 3–4:53–61. (In Russ.)].Шостак Н.А., Клименко А.А. Нестероидные противовоспалительные препараты – современные аспекты их применения. Клиницист 2013;3–4:53–61. [Shostak N.A., Klimenko A.A. Non-steroidal antiinflammatory drugs: modern aspects of their application. Klinitsist = Clinicist 2013; 3–4:53–61. (In Russ.)].